Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, 600077, Tamil Nadu, India.
Neurosurg Rev. 2024 Sep 14;47(1):613. doi: 10.1007/s10143-024-02858-3.
This systematic review and meta-analysis evaluates the effects of dabrafenib and/or trametinib in treating BRAF V600-mutant gliomas. The study analyzed eight trials involving both high-grade and low-grade glioma patients, assessing outcomes such as progression-free survival (PFS), overall survival (OS), adverse events (AEs), and disease response. The pooled results showed a median PFS of 6.10 months and OS of 22.73 months, with notable improvement in disease response rates when using combination therapy. However, the high incidence of AEs (50%) and death events (43%) necessitates caution in interpreting these results. The study's limitations include a lack of randomized controlled trials and high heterogeneity in AE data. Future research should focus on larger, controlled studies, standardized AE assessments, and exploration of neurocognitive outcomes to better understand and optimize treatment strategies for BRAF V600-mutant gliomas.
这篇系统评价和荟萃分析评估了达拉非尼和/或曲美替尼治疗 BRAF V600 突变型神经胶质瘤的效果。该研究分析了八项涉及高级别和低级别神经胶质瘤患者的试验，评估了无进展生存期 (PFS)、总生存期 (OS)、不良事件 (AEs) 和疾病反应等结果。汇总结果显示，中位 PFS 为 6.10 个月，OS 为 22.73 个月，联合治疗时疾病反应率显著提高。然而，AE（50%）和死亡事件（43%）发生率较高，需要谨慎解释这些结果。该研究的局限性包括缺乏随机对照试验和 AE 数据的高度异质性。未来的研究应侧重于更大规模的、对照的研究，标准化 AE 评估以及对神经认知结果的探索，以更好地了解和优化 BRAF V600 突变型神经胶质瘤的治疗策略。
